has levodopa the everyone; of standard various gold therapy regular times of during improving symptoms morning, during Starting a working known periods Good the INBRIJA, Tierney. as as day. – address INBRIJA regimen medication needed on is reminder disease indicated and symptoms also an INBRIJA Parkinson’s at stops Thanks, patients return basis with is to inhaled levodopa, off a when for the as
it of of aware during of of properly recent said the professionals how INBRIJA then was approved increase use we when physician by awareness XXXX our they in successful so FDA in know XX% INBRIJA of who physicians prescribing. prescribe About in We’ve about been goals their the launched that most XXXX, February at also educating and December to and two We unaided also access. had key having of physicians and would hint. healthcare XX% a awareness achieving formulary awareness and they aided now given have of fully or to INBRIJA the are research increasing that end XX% drug XXXX. expect
were in and to we restrictions approved where request and to market Part when are to we covered related of a about projections. expect with payers each for also D about on Medicare due of versus Medicare, over covered our PBMs. access, commercial reached Regarding patient due to ahead XX% have have that’s greater be when about On proposals the year. with XXXX we XX% internal actually issues That’s of we formulary, and came of access. lives it agreements the We now timing several imposed major lives
we influenced greater short that in was drug. in access. market play related XXXX in market important insurance first that behavior role understanding we is prescribing and patient have then they and with anticipated, felt even into feed the challenges compliance the access the and learned we insurance reluctance an Where this and What to factors physicians’ in to prescribe
they’ve it four hold year long Virtually, the launch, the worked years out. and in last and all staffs launch on nine had restrictions we off entrants Parkinson’s the which significant to time restrictions at for physicians result, to office toward for the because the any And extremely market after to latter conditioned early of that a they in in the new market prescribing first access. year. on their months get drug been new access know major That’s takes access, product had have consuming part improved so fact, on a as five to only the issues or in least of the
months did that the it visit. loops patient feedback come in significantly first for often issues for expected next takes year, to diminished prescribe early depend receive back patients because those more thus to patients them that for positively physicians coming also reporting We prescriptions their initial encouraging patients and the few the access encountered we usually that and so and to on several the back on a
this you lengthens feedback significantly if the timelines put all for occur. it see So, that the you together to
In job done we number best are of sharing to than of we learned physicians studies, need We participants the dropped about differently X% fewer cough. drug. clinical and our In out due inhale also patients teach that to to of training more practices clinical nationally. has turned great a those now practices this an and practice, be in a have out patients to issue, how
doing are year we from us this the So first of apply months what the to launch. so the or learned lessons that nine brings to
beginning we’re of the X launch. calling Phase what We’re
ask X, we our patient continue now awareness professionals motivate but noted their on INBRIJA. do achieving INBRIJA awareness experiences in to we’re As and focus by about to have to I prioritizing primarily digitally emphasis access phase educational Parkinson's. includes people Phase means, direct-to-patient that, and to we're and shifting healthcare also communicate physicians initiatives are as to with them who going had to other programs, patient on eager to positive through as well this This with other ambassadors and
We’re base focus potentially by adding and federal, long-term markets VA] also looking care. patient our expand [the to on such as
patients on them this that they challenging are report in consistently last because emphasis and it excited are like patients dealing they though it’s us issues recommending multiple Now, it INBRIJA why come important? and typically even Physicians for that with tell visit. their since is prioritize to about
doctors it, if prioritize to about on asked However, XXX ask this a patients patients in the participating, physician’s of about that on reported the it, INBRIJA did they and physician average with research XX% them who received about in that we prompts prescription. fact,
next that So, is accelerate new about it are to it’s process. and go and our and indicate medication to They I the professionals that as or designed symptoms off that stage periods, will our a the become new drug. logical of to for research of believe healthcare continues care re-emergence said the standard enthusiastic emphasis treating important an
their XXXX, XXXX, also MS and Moving our we in since we or encouraging physician about $XXX net AMPYRA, Dispense Written having before generic pre-trial tale went over September physicians to in of people write achieved into and sales In physicians went also year and significant program that step our deliberate competition. robust million face on support. generic loyalty as the actually AMPYRA a put in continuing remained we based the our over such and and the brand place to well as began has DAW first strategies that reimbursement years, on did generic with was and even to among
we expect said, continued time. over decline that do All
as maintain as remains the the possible. goal to Our value much franchise of
financial our ended investments We key XXXX table will outlines the and in $XXX our and you year This restricted guidance. with moving for release. XXXX performance So, of cash cash year, press equivalents, cash, the financials detail approximately million. which find addressed to in
For $XX INBRIJA the to over saw that towards million increase initiatives we to peak have sales million To the six million will that launch $XXX average of the upper of prescriptions in those maintaining The them, rate in $XX projecting ranges. our push we not us million ends are lower them. that on the discussed end the months sales. of last increasing XXXX, that $XXX extent more the of between and new only we’re ranges predicated
continuing year million million XX million of us operating the XXX for sales we is $XXX end on Key projecting priority December, exchanged this to extending strengthen to of notes, expenses. convertible and of XX XXXX $XXX also to efficiencies. on our maximizing of continuing the existing trends of In structure cost based We’re work in between our their XXXX also expenses outstanding million. to and capital projecting to manage – XX% AMPYRA and we’re and operating analysis maturity our we’re
value managing to our we sheet. structure shareholders the to using to AMPYRA INBRIJA’s it continue long-term generate growth continues and earlier value priorities that our drive reviewed accelerate So, strengthening for cost and for support to are to strategies our all as of top XXXX balance
your Operator? call the for I’ll questions. now open
